Chimin Health Management Co., LTD. (hereinafter referred to as the "Chimin") is a modern pharmaceutical enterprise founded in 1996, with a registered capital of 3.2 million yuan. It is a key backbone enterprise in the pharmaceutical industry of Zhejiang Province and a national high-tech enterprise. It was listed on the Shanghai Stock Exchange in February 2015 (SH.603222).The company is located in Zhejiang Huangyan high-tech development park, covering an area of nearly 400 mu, with a total number of 2,073 employees.

Since its listing, Chimin has actively laid out its "Comprehensive health strategy", covering three fields such as pharmaceuticals, medical devices, and comprehensive medical services. The company has initially established a strategic pattern of "one main and two wings" with medical services as the leading role and pharmaceuticals and medical devices cooperating development.At present, the company has jurisdiction over three production bases in Zhejiang, Shanghai and Spain, and 9 wholly-owned or holding subsidiaries such as Boao International Hospital.

The company has nearly 40 kinds of infusion products, including balance, nutrition, therapeutic infusion and external rinse.Jumin Biotechnology Co., Ltd. is a wholly-owned subsidiary with a production base of 250 mu in Shanghai Fengxian, which is one of the largest disposable sterile medical device manufacturers planned in China.The leading chemical pharmaceutical product "double-pipe and double-valve non-PVC soft bag" infusion occupies more than 30% of the market share in East China and South China, and is sold abroad in more than 30 countries and regions including Southeast Asia, Africa and South America."Medical non-PVC film material", has the national invention patent. The leading product of medical devices is the automatic retractable safe self-destruct syringe. It cooperates with the American medical device giant RTI Company and the United Nations Red Cross. The technical level is internationally advanced.

Among them, the comprehensive medical service sector consists of 18 hemodialysis centers and 3 general hospitals (Boao International Hospital, second Hospital of E'zhou, Hubei Province, yuncheng New Friendship Hospital, Shandong Province).The boao international hospital opened on May 18, 2018. It has the genomic medicine and regenerative medicine as the core, combined the minimally invasive research institute and university of Turin, Italy. The hospital also introduced the Nobel Prize scientists professor Michael Ross, Wu Zuze academician of Chinese Academy of Sciences, and Liao Wanqing to establish the academician workstation.

Chimin will continue to focus on the layout of comprehensive and specialized hospitals (tumor, kidney disease, etc.), committed to building the company into a first-class medical group in China.In terms of medical devices, in addition to injection puncture devices such as syringes and infusion sets, the company obtained the production license of medical devices for hemodialysis concentrate in November 2017, which effectively supplemented the product line of medical devices.In vitro diagnosis, the company's wholly-owned subsidiary, Spain LINEAR, mainly research and development and production of in vitro diagnosis products and biotechnology products, with 4 European patents, products have been sold to the European Union, the United States and more than 20 countries.